. Author manuscript; available in PMC: 2018 Feb 23.

Published in final edited form as: Thromb Haemost. 2016 Dec 22;117(3):618–624. doi: 10.1160/TH16-07-0519

Table 4.

Attenuation of the Association of D-dimer with Cardiovascular Disease by CRP^*

	Stroke			CHD
	Per Doubling of D-dimer		Percent Decrease in HR (Without - With CRP)	Per Doubling of D-dimer		Percent Decrease in HR (Without - With CRP)
	HR for D-dimer	HR for D-dimer adjusted for CRP	Percent Decrease in HR (Without - With CRP)	HR D-dimer	HR for D-dimer adjusted for CRP	Percent Decrease in HR (Without - With CRP)
All	1.15 (1.01, 1.31)	1.13 (0.99, 1.29)	13.3% (0.0%, 40.0%)	1.27 (1.11, 1.45)	1.22 (1.05, 1.40)	22.7% (5.5% 41.1%)
Blacks	1.12 (0.92, 1.34)	1.08 (0.89, 1.31)	33.3% (0.0%, 67.5.0%)	1.33 (1.11, 1.59)	1.28 (1.06, 1.55)	15.1% (0.6%, 33.0%)
Whites	1.19 (0.99, 1.42)	1.17 (0.98, 1.40)	10.5% (0.0%, 27.9%)	1.21 (1.01, 1.47)	1.15 (0.94, 1.40)	28.5% (6.7%, 61.9%)

CHD: Adjusted for age, sex, region, race, systolic blood pressure, use of antihypertensive medications, diabetes, current smoking, total cholesterol, HDL cholesterol, and taking cholesterol-lowering medications

Stroke: Adjusted for age, sex, region, race, age*race, systolic blood pressure, use of antihypertensive medications, diabetes, current smoking, baseline cardiovascular disease, baseline atrial fibrillation, and baseline left ventricular hypertrophy